A Single/Multiple Dose Escalation, Open-Labeled, Phase I Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB1001 in Patients With Acute Optic Neuropathy
Latest Information Update: 23 Jul 2024
At a glance
- Drugs FB 1001 (Primary)
- Indications Angle-closure glaucoma; Optic nerve disorders
- Focus Adverse reactions
Most Recent Events
- 23 Jul 2024 New trial record